Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/35VFDN4
via IFTTT